UNIVERSITY HEALTH NETWORK

There is described herein methods of ameliorating, treating or preventing graft-versus-host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human using innate lymphoid cells (ILCs), including compositions comprising ILCs and methods for making the same.

There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

There is described herein a method of prognosing or classifying a subject with a Myeloproliferative Neoplasm (MPN) comprising: (a) determining the expression level of at least 10 genes in a test sample from the subject selected from the group consisting of SPP1, CEACAM6, GJA1, IGSF10, IGFBP2, COL4A5, LYVE1, MTIE, EMP1, XIST, DLK1, TPSAB1, TIMP3, CLC, MS4A1, ENKUR, ALOX12, KNDC1, HLA-DQB1, GAS2, CLEC2L, BEND2, CDH7, and NT5E; and (b) comparing expression of the at least 10 genes in the test sample with reference expression levels of the at least 10 genes from control samples from a reference cohort of patients; wherein a difference or similarity in the expression of the at least 10 genes in the test sample and the reference expression levels is used to prognose or classify the subject with MPN into a low risk group or a high risk group for worse survival.

There is described herein a nanoparticle comprising an outer shell comprising a porphyrin salt, an expanded porphyrin salt or an analog of porphyrin salt, around an inner oil core.

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind free immunoglobulin light chains (FLC), polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of measuring FLC in a biological sample comprising contacting the sample with the anti-FLC antibody. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-FLC antibody to a subject in need thereof.

The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

Systems and methods for filtering time-varying data for filtering and extracting a predicted physiological signal. A method including: segmenting the time-varying data into temporal windows; using a trained filter machine learning model, predicting an error for each prediction of the physiological signal for each window of time-varying data, the filter machine learning model trained using physiological signal predictions based on training time-varying data and known values of the physiological signal for the training time-varying data; discarding each window of time-varying data when the predicted error for such window is greater than a threshold; and where the window of time-varying data is not discarded, outputting at least one of the window of time-varying data and the predicted error for each prediction of the physiological signal.

A method for fluorescence-based imaging of a target to detect contamination and/or pollutants is disclosed. The method includes labelling a pre-selected biomarker at the target, illuminating the target with excitation light emitted by an excitation light source and having at least one wavelength or wavelength band causing at least the pre-selected biomarker to fluoresce, detecting fluorescence emissions of at least the pre-selected biomarker with an image detector of a handheld imaging device, and determining the presence, location, and/or quantity of contamination and/or pollutants on and/or in the illuminated target based on the detected fluorescence emissions of at least the pre-selected biomarker.